Phase II Trial of PS-341 (NSC 681239) Followed by the Addition of Doxorubicin at Progression in Advanced Adenoid Cystic Carcinoma of the Head and Neck.
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2013
At a glance
- Drugs Bortezomib (Primary) ; Doxorubicin (Primary)
- Indications Adenoid-cystic-carcinoma; Head and neck cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 13 Nov 2007 Status changed from in progress to completed.
- 23 May 2007 Status changed from in progress to recruiting.